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Objectives This study sought to evaluate the 30-day and long-term clinical outcomes of patients
with carotid obstructive disease (COD) and concomitant coronary artery disease (CAD) undergoing a
combined percutaneous revascularization, in 4 high-volume centers skilled for the treatment of mul-
tilevel vascular disease.
Background The optimal management of patients with COD and concomitant CAD remains contro-
ersial. A variety of therapeutic strategies, including coronary artery bypass grafting, alone or in
ombination with carotid artery revascularization, have been reported.
ethods Between January 2006 and April 2010, 239 consecutive patients with COD (symptomatic
arotid stenosis in 20.5%) and concomitant CAD were treated with staged or simultaneous carotid
rtery stenting and percutaneous coronary intervention, and enrolled in this prospective registry.
he primary endpoint was the incidence of major cardiac and cerebrovascular events, including any
eath, myocardial infarction, or stroke occurring between the ﬁrst revascularization procedure and
0 days after treatment of the second vascular territory affected.
esults The incidence of the primary endpoint at 30 days was 4.2% (95% conﬁdence interval [CI]:
.02 to 7.56). The rate of death, myocardial infarction, and stroke at long-term follow-up (median
20 days) was 4.2%, 2.1%, and 3.8%, respectively. At long-term follow-up, patients with previous
ardiovascular disease had signiﬁcantly higher rates of major cardiac and cerebrovascular events
han did patients with a ﬁrst clinical episode (17% vs. 6%, hazard ratio: 3.34; 95% CI: 1.46 to 7.63;
 0.004).
Conclusions In patients with COD and concomitant CAD, a combined percutaneous treatment
compares favorably with previous surgical or hybrid experiences. Such strategy may be particularly
suited to complex patients at high surgical risk. (J Am Coll Cardiol Intv 2011;4:560–8) © 2011 by
the American College of Cardiology Foundation
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561The coexistence of atherosclerosis in the coronary and
carotid districts is a pathological condition that continues to
expand in parallel with life expectancy (1,2). However, in
he absence of randomized trials, the optimal treatment of
atients with severe carotid obstructive disease (COD) and
oncomitant coronary artery disease (CAD) is not well
stablished (3,4). A variety of therapeutic strategies, includ-
ng coronary artery bypass graft (CABG), alone or associ-
ted with staged or simultaneous carotid endarterectomy
CEA) (5) or carotid artery stenting (CAS) (6), have been
eported in different patient groups. Nevertheless, the inci-
ence of death, stroke, or myocardial infarction (MI) with
uch strategies is high and varies from 7% to 14% (3–6).
Although a direct comparison of percutaneous to surgical
oronary and/or carotid artery revascularization may not be
alid in patients with CAD and concomitant COD, as these
rocedures are likely to be performed in different patient
roups based on anatomical and clinical features, CAS and
ercutaneous coronary intervention (PCI) have recently
roved to be accepted alternatives to CEA and CABG in
igh surgical risk patients (7–11). Indeed, CAS has been
hown to course with less MI despite a statistically signifi-
ant increment of stroke when compared with CEA (9),
upporting the concept that CAS may be safer in patients
ith atherosclerosis extended to the coronary district. By
ontrast, PCI has been demonstrated to be at least equiva-
ent to CABG in terms of death, stroke, or MI (10), and it
s particularly suited in patients with unstable clinical
resentation or with multiple comorbidities that increase
he intraoperative surgical risk (11). Furthermore, the pres-
nce of COD is associated with a significant increase in
eath and stroke in patients undergoing CABG (12,13).
Because it has the least invasive nature, a combined
ercutaneous revascularization in patients with significant
OD and CAD might be particularly appropriate for such
complex subset of patients at high surgical risk. Thus, the
im of this study was to evaluate the early and long-term
utcomes of a combined percutaneous revascularization
trategy in a population of patients with COD and con-
omitant CAD, treated by CAS and PCI, in 4 high-volume
enters skilled for the treatment of multilevel vascular
isease, which comprise the FRIENDS (Finalized Research
n Endovascular Strategies) Study Group (14).
ethods
FRIENDS is a spontaneously generated, independent, not-
for-profit working group. Present members are engaged at
high-volume Italian institutions, committed to cardiovascu-
lar care, and work with a shared intention under common
coordination (14). The FRIENDS study is the first large,
multicenter registry including 659 patients with combined
COD and CAD undergoing percutaneous, hybrid, or sur-
gical revascularization treatments. The 30-day results of the ioverall population have been reported previously (15). This
eport presents the short- and long-term outcomes in the
re-specified subgroup of patients (n  239) undergoing a
ombined percutaneous revascularization.
Patient population. In this prospective, multicenter, non-
andomized study, we enrolled consecutive patients sched-
led for carotid and coronary angiography on the basis of
linical symptoms, noninvasive diagnostic tests for myocar-
ial ischemia, and carotid Doppler ultrasound findings, and
ho were suitable candidates for CAS and PCI in each
articipating center. Patients were extracted from the com-
on FRIENDS database, which was designed to abridge
ndividual datasets collected in each center. All patients
ncluded in this study gave informed consent to undergo the
roposed treatment and follow the pre-specified follow-up
rogram. The ethical commit-
ees of each participating insti-
ution were informed about the
ims and methods of this study.
Each of the participating cen-
ers developed a local team of
xperts in vascular medicine to
ointly evaluate the therapeutic
ndications in this specific pa-
ient setting (14). The cardio-
ascular team included cardiac
nd vascular surgeons, clinical
nd interventional cardiologists,
nd neurologists. To be enrolled
nto the study, patients had to be
onsidered suitable for PCI and
AS by the cardiovascular team
fter diagnostic coronary and
ervical-cerebral angiography
erformed according to standard
echniques. Patients were con-
idered eligible for PCI if they
resented documented myocar-
ial ischemia and at least a sig-
ificant angiographic stenosis 70% in 1 of the major
oronary branches. According to clinical presentation, CAD
as classified as stable (including patients with silent isch-
mia) or acute coronary syndromes (ACS), including pa-
ients with unstable angina, non–ST-segment elevation
yocardial infarction, and ST-segment elevation myocar-
ial infarction. Neurologically asymptomatic and symptom-
tic patients were considered eligible for CAS if they
resented a stenosis involving the internal carotid artery at
elective angiography of 70% or 50%, respectively.
atients were considered neurologically symptomatic if an
psilateral cerebrovascular event (including transient isch-
mic attack, amaurosis fugax, ischemic stroke, or retinal
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
CAS  carotid artery
stenting
CEA  carotid
endarterectomy
CI  confidence interval
COD  carotid obstructive
disease
MACCE  major cardiac and
cerebrovascular event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TIA  transient ischemic
attack(s)nfarction) had occurred within the prior 6 months.
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562Percutaneous revascularization strategy and technique. Si-
multaneous interventions were considered as those per-
formed during the same access to the catheterization labo-
ratory, or within the same day. In cases of very complex
vascular access or concomitant acute severe carotid and
coronary syndromes, CAS was combined with PCI during
the same procedure (16). Staged interventions were in-
ended as those performed within a range of 1 to 45 days
rom the first procedure. The sequence of interventions was
stablished on an individual patient basis by the cardiovas-
ular team, usually according to clinical symptoms of the
atients and after diagnostic coronary and cervical-cerebral
ngiography. The first percutaneous procedure was per-
ormed on the priority vascular district immediately after the
iagnostic angiography and during the same access.
According to standard clinical practice, PCI was per-
ormed via a 6- or 7-F sheath in the femoral or radial artery.
rocedural success was defined as an angiographic residual
iameter stenosis 20% by visual estimation, without the
ccurrence of cardiac death, Q-wave or non–Q-wave MI, or
epeat revascularization of the target lesion during the
ospital stay. In patients with multivessel CAD, the most
omplete degree of revascularization was attempted, unless
ontraindicated by severe comorbidities or particularly un-
avorable anatomy.
The CAS procedures were performed via a 7-, 8-, or 9-F
heath in the femoral artery by positioning a guiding
atheter in the common carotid artery, proximally to the
ifurcation. If this was not possible due to the particular
natomy of supra-aortic vessels, a stiff wire was placed into
he external carotid artery, for positioning of a long sheath
r a guiding catheter (coaxial technique) into the common
arotid artery. Cerebral protection with filter wires or with
roximal occlusion devices was used in all patients. Different
ypes of self-expandable stents were used according to
ndividual clinical and anatomical characteristics as recom-
ended by experts (17). After stent deployment and atro-
ine administration, stents were post-dilated with a balloon
5.0 to 7.0 mm) to achieve a residual stenosis 30%.
Pre-procedural antithrombotic therapy consisted of aspi-
in and heparin at standard dosages and clopidogrel at a
oading dose of 300 mg. In case of staged procedures, aspirin
nd clopidogrel were not discontinued between the first and
econd interventions. After the percutaneous procedure,
ual antiplatelet therapy (aspirin 100 mg/day and clopi-
ogrel 75 mg/day) was maintained for 1 month in all
atients and was extended to 12 months after drug-eluting
tent implantation and in all patients presenting with ACS
egardless of the type of coronary stent. Aspirin alone was
dvised indefinitely in all cases.
Study endpoints. The primary endpoint of the study was
he incidence of major cardiac and cerebrovascular events
MACCE), including any death, MI, or stroke occurring Wetween the first revascularization procedure and 30 days
fter treatment of the second vascular territory affected.
Secondary endpoints were the cumulative incidence of
ACCE, transient ischemic attacks (TIA), major bleeding,
cute kidney injury at 30 days after both procedures, and the
ncidence of MACCE at long-term follow-up.
Endpoint deﬁnitions. Deaths were considered irrespective of
heir etiology. Fatal stroke (ischemic or hemorrhagic) and
atal MI were defined as deaths. Nonfatal MI included
eriprocedural MI (diagnosed by a rise in creatine kinase-
yocardial band fraction of 3 the upper limit of normal),
einfarction (defined as recurrence of symptoms together
ith ST-segment elevation or new left bundle branch block
nd an increase in cardiac enzymes after stable or decreasing
alues), or spontaneous MI (diagnosed by any rise in
reatine kinase-myocardial band fraction above the upper
imit of normal). Electrocardiograms and cardiac enzymes
ere assessed routinely after both PCI and CAS procedures.
Stroke was defined as an acute ischemic neurological
vent that persisted 24 h, as assessed by a neurologist and
onfirmed by brain imaging. Strokes were considered dis-
bling (major) if patients had a modified Rankin score of
3 at 30 days after onset of symptoms. A minor stroke was
efined as a Rankin score of 3 or less that resolved completely
ithin 30 days. Amaurosis fugax and TIAs were diagnosed
f the symptoms disappeared within 24 h. The neurological
tatus was assessed by a neurologist before and after CAS
rocedures in all cases.
Acute kidney injury was intended as a rise in serum
reatinine of 0.5 mg/dl or a 25% increase from the
aseline value, assessed at 72 h after CAS and PCI (18).
ajor bleeding was defined according to recent interven-
ional trials (19).
Data collection and patient follow-up. Patients’ data were
ntered in a common dedicated database. Clinical follow-up
as obtained prospectively by either clinical visits or tele-
honic contacts at 30 days after both procedures and
hereafter at 6-month intervals.
Statistical analysis. Continuous data are expressed as mean 
D or median (interquartile range), where appropriate;
iscrete variables are given as absolute values and percent-
ges. Univariate analysis to test the relation between the
linical and treatment variables and the occurrence of events
ncluded in primary and secondary endpoints were per-
ormed by means of binary logistic regression, obtaining also
he odds ratio for each parameter. The association between
linical and treatment variables and MACCE at 2-year
ollow-up was assessed by means of a Cox proportional
azards regression analysis.
Kaplan-Meier survival tables and plots were also pro-
ided. A probability value of0.05 for 2-sided statistics was
onsidered significant. SPSS (version 15, IBM Corporation,
omers, New York) and Excel (Microsoft, Redmond,
ashington) were used for data analysis.
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563Results
Between January 2006 and April 2010, 239 consecutive
patients with COD and concomitant CAD referred to our
hospitals were eligible for both CAS and PCI. The baseline
clinical characteristics of all patients are reported in Table 1.
Most patients were men, 76 patients (32%) had ACS, and
99 patients (41%) had multivessel CAD. Symptomatic
COD was present in 49 (20.5%) patients. Procedure-related
characteristics are shown in Table 2.
30-day outcomes. Table 3 details the occurrence of clinical
vents that comprised the primary and secondary endpoints.
he primary endpoint of the study occurred in 4.2% (95%
onfidence interval [CI]: 2.02 to 7.56) of patients. The
ncidence of death, MI, and stroke was 0.4%, 1.3%, and
.5%, respectively. One patient with symptomatic COD
ied 2 days after a simultaneous treatment of CAD and
Table 1. Baseline Characteristics of the Patients (n  239)
Age, yrs 73.13 7.77
Age 80 yrs 52 (22)
Male 182 (76)
Hypertension 207 (87)
Diabetes 89 (37)
Hypercholesterolemia 181 (76)
Smoking 103 (43)
Family history of CAD 37 (15)
Chronic kidney disease* 30 (13)
Previous MI 51 (21)
Peripheral artery disease 25 (10.5)
LVEF 56.90 6.36
Previous CABG 10 (4)
Previous PCI 18 (7.5)
ACS 76 (32)
Chronic stable angina 55 (23)
Extension of CAD
1-vessel disease 140 (58)
2-vessel disease 59 (25)
3-vessel disease 40 (17)
Unprotected left main 8 (3)
Symptomatic COD 49 (20.5)
Previous stroke 6 (2.5)
Bilateral carotid stenosis 70% 42 (18)
Previous CEA 13 (5)
Previous CAS 7 (3)
Previous MI, stroke, or carotid/coronary revascularization 88 (37)
ACS or symptomatic COD 118 (49)
Dual APT 230 (96)
Statin use 180 (75)
Values aremean SD or n (%). *Defined as an estimated glomerular filtration rate of60ml/min
per 1.73 m2.
ACSacute coronary syndrome(s); APTantiplatelet therapy; CABG coronary arterybypass
graft; CAD  coronary artery disease; CAS  carotid artery stenting; CEA  carotid endarterec-
tomy; COD carotid obstructive disease; LVEF left ventricular ejection fraction; MImyocar-dial infarction; PCI percutaneous coronary intervention.OD, after ventricular fibrillation due to a possible coro-
ary stent thrombosis. Three nonfatal periprocedural MIs
ccurred in patients undergoing multivessel PCI within 30
ays after successful CAS. Four patients with asymptomatic
OD (1.7%) already treated by PCI had a major ipsilateral
troke after CAS: 3 patients within 6 h after the procedure
nd 1 patient 7 days after discharge. Two patients (0.8%)
ad a minor stroke a few hours after CAS.
The secondary endpoint after both procedures oc-
urred in 20 patients (8.4%). In particular, TIA occurred
n 6 patients (2.5%), major bleedings in 3 patients (1.3%),
nd acute kidney injury in 1 patient (0.4%). The results of
he univariate analysis to test the relation between the
Table 2. Procedure-Related Characteristics
Staged procedures 201 (84)
Time between the staged procedures, days 23.6 24.6
Simultaneous procedures 38 (16)
Sequence of the procedure: PCI ﬁrst 192 (80)
PCI procedure success rate 235 (98)
Number of coronary stents implanted per patient 1.4 0.3
Patients treated with 1 DES 148 (62)
CAS success rate 238 (99.6)
Cerebral protection device
Filter wire 218 (92)
Proximal occlusion (Mo.Ma system, Invatec,
Roncadelle, Italy)
20 (8)
Type of carotid stent
Carotid Wallstent (Boston Scientiﬁc,
Natick, Massachusetts)
116 (49)
AccuLink (Abbott Vascular, Santa Clara, California) 76 (32)
X-ACT (Abbott Vascular) 16 (7)
Precise (Cordis, Bridgewater, New Jersey) 22 (9)
Cristallo Ideale (Invatec) 8 (3)
Values are n (%) or mean SD.
DES drug eluting stent(s); other abbreviations as in Table 1.
Table 3. Hierarchical Events at 30 Days From the Last Procedure
All deaths 1 (0.4)
Cardiac deaths 1 (0.4)
Neurological deaths 0 (0)
Other cause 0 (0)
Nonfatal MIs 3 (1.3)
All strokes 6 (2.5)
Major ipsilateral nonfatal strokes 4 (1.7)
Major contralateral nonfatal strokes 0 (0)
Minor strokes 2 (0.8)
MACCE (any death, MI, or stroke) 10 (4.2)
Transient ischemic attacks 6 (2.5)
Major bleedings 3 (1.3)
Acute kidney injury 1 (0.4)
Any of the above 20 (8.4)
Values are n (%).MACCEmajor cardiac and cerebrovascular event(s); MImyocardial infarction.
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564Figure 1. Univariate Linear Regression Analysis for the Occurrence of 30-Day Events Included in Primary and Secondary Endpoints
Univariate linear regression analysis for the occurrence of 30-day events included in primary (A) and secondary (B) endpoints. Numbers indicate the odds ratio
(95% conﬁdence interval) and the signiﬁcance level (p) for each parameter. ACS  acute coronary syndrome(s); CAD  coronary artery disease; CAS  coronary
artery stenting; COD  carotid obstructive disease; CVD  cardiovascular disease (including previous stroke, myocardial infarction, or carotid/coronary surgical or
endovascular revascularization); LV  left ventricular; PCI  percutaneous coronary intervention.
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565clinical and treatment variables and the occurrence of
events included in primary and secondary endpoints are
shown in Figures 1A and 1B. Of note, the incidence of
MACCE was not statistically different in patients treated
with a simultaneous or staged approach (2.6% vs. 4.5%,
p  0.60), in patients treated by PCI first or by CAS first
(3.1% vs. 8.5%, p  0.10), in patients with symptomatic or
asymptomatic COD (6.1% vs. 3.7%, p 0.45), in patients older
or younger than 80 years (5.8% vs. 3.7%, p  0.52), in patients
with ACS or chronic stable CAD (2.9% vs. 4.7%, p 0.55), and
in those with multivessel or single-vessel CAD (4.4% vs. 4.0%,
p  0.88).
The cumulative incidence of MACCE, TIA, major
bleeding, and acute kidney injury was higher in patients
with previous cardiovascular disease (previous MI, stroke, or
carotid/coronary revascularization) than in patients with a
first clinical episode (12.5% vs. 8.3%, p  0.05) and,
lthough not statistically significant, in patients older than
0 years (13.5% vs. 6.4%, p  0.1).
Long-term follow-up. Median follow-up was 520 days (inter-
quartile range: 416 to 812 days), with 204 of the patients
(85.4%) being followed up for at least 1 year. The cumulative
incidence of death, MI, and stroke was 4.2%, 2.1%, and 3.8%,
respectively. The occurrence of MACCE after the first 30 days
from the last procedure was 5.8% (Table 4). In particular, of 9
deaths (3.8%), 2 deaths (0.8%) were cardiac related, 1 (0.4%)
was neurological, and 6 (2.5%) were of other causes. Two
(0.8%) nonfatal MI and 3 strokes (1.2%) occurred: 2 (0.8%)
major ipsilateral nonfatal strokes, and 1 (0.4%) minor stroke.
Cumulative MACCE-free survival at 2 years was 82.3 3.8%
(SE). The Kaplan-Meier curve for 2-year freedom from death,
all stroke, and MI is shown in Figure 2.
The results of the univariate analysis to test the relation
etween the clinical and treatment variables and the occurrence
Table 4. Hierarchical MACCE at 2-Year Follow-Up
Event
After 30 Days From
the Last Procedure All MACCE
All deaths 9 (3.8) 10 (4.2)
Cardiac deaths 2 (0.8) 3 (1.2)
Neurological deaths 1 (0.4) 1 (0.4)
Other cause 6 (2.5) 6 (2.5)
Nonfatal MIs 2 (0.8) 5 (2.1)
All strokes 3 (1.2) 9 (3.8)
Major ipsilateral
nonfatal strokes
2 (0.8) 6 (2.5)
Major contralateral
nonfatal strokes
0 (0) 0 (0)
Minor strokes 1 (0.4) 3 (1.2)
MACCE (any death, MI,
or stroke)
14 (5.8) 24 (10.0)
Values are n (%). The second column refers to the events that occurred after 30 days from the last
procedure, whereas the third column summarizes all MACCE from day 0 to long-term follow-up.tAbbreviations as in Table 3.f MACCE at long-term follow-up are shown in Figure 3.
atients with previous cardiovascular disease had significantly
igher rates of MACCE than those with a first clinical episode
17.0% vs. 6.0%; hazard ratio: 3.34; 95% CI: 1.46 to 7.63,
 0.004). The Kaplan-Meier curve for 2-year cumulative
ACCE free survival in these 2 groups is shown in Figure 4.
iscussion
This prospective, multicenter study demonstrates that in
patients with CAD and concomitant COD, a combined
percutaneous revascularization treatment yields good imme-
diate and long-term results.
Our research discloses the largest available series of its
kind; it reinforces the concept of feasibility demonstrated in
previous small series (20,21); and it compares favorably to
similar populations treated by either totally surgical (5,12)
or hybrid revascularization strategies (6,13,22–24). For in-
tance, the 30-day rate of death/stroke/MI reported in a
arge meta-analysis of published studies on CAS plus
ABG procedures was 9.4% (95% CI: 7.0 to 11.8) (6),
hich is about 2 the number of incidences reported in the
resent study.
Despite some obvious baseline differences when com-
ared with series of patients needing CABG, it is worth
oting that our results were obtained in a population of
atients with several comorbidities, and who were treated
ith multiple coronary interventions in over 40% of cases.
he high rate of freedom from death, stroke, or MI during
Figure 2. Kaplan-Meier Analysis for Cumulative Survival Free of
MACCE at 2-Year Follow-Up
Estimated survival was of 82.3%  3.8% (SE). MACCE  major cardiac and
cerebrovascular event(s).he 2 years of follow-up supports the long-term efficacy of
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566this combined percutaneous strategy. Nonetheless, as ex-
pected, patients with more advanced cardiovascular disease,
that is, those with previous stroke, MI, or carotid/coronary
(surgical or percutaneous) revascularization, exhibited worse
short- and long-term outcomes. Indeed, according to recent
findings (9), elderly patients exhibited a higher incidence of
adverse events at 30 days, although this difference did not
reach a statistical significance, probably due to the relatively
small sample size of our series.
Notably, the low incidence of periprocedural complica-
tions is likely to be also related to the experience developed
in dedicated centers and might not be easily and immedi-
ately replicable outside similar contexts. Indeed, the
FRIENDS Study Group is committed to vascular care,
according to well-defined standards by which all patients are
evaluated by a cardiovascular team after diagnostic coronary
and cervical-cerebral angiography according to a “case-
tailored” approach (17). In all CAS procedures, materials,
devices, and techniques were matched to specific lesions or
anatomies. Among patients with multivessel CAD, physi-
cians pursued the most complete degree of revascularization
and optimal stent implantation. The sequence of the pro-
cedures and the strategy (staged or simultaneous) were
established by the cardiovascular team on an individual
patient basis. Finally, the optimal medical treatment on top
of interventions, as well as a tight clinical follow-up focused
Figure 3. Univariate Cox Regression for the Occurrence of Major Cardiac a
Numbers indicate the hazard ratio (95% conﬁdence interval) and the signiﬁcanon secondary prevention was achieved in almost all patients. oAll these factors play an important role on the long-term
outcome of vascular interventions and may have influenced
our results.
Therefore, compared with previous experiences with
surgical or hybrid revascularization strategies, this com-
bined percutaneous approach offers the following advan-
tages. 1) Its less invasive nature may prove particularly
appropriate for complex patients (i.e., those with more
advanced cardiovascular disease), who are suited for percu-
taneous treatment. 2) The sequence of the 2 procedures is
easier to plan, and in most cases, coronary revascularization
can be safely performed first (unless otherwise recom-
mended, as in patients with severe symptomatic COD),
without an increased risk of stroke. Indeed, evidence in
support of coronary revascularization in patients needing
carotid interventions is becoming more consistent (25),
although it remains to be proved in large randomized
clinical trials. 3) The shorter hospital stay might translate
into a reduction in costs compared with the costs of hybrid
or surgical strategies.
Study limitations. First, the results of this study, performed
t high-volume centers, may not be extrapolated to less
xperienced centers. Second, due to the relatively small
ample size, the low rate of events and the presence of only 1
ndependent predictor of MACCE at univariate analysis, the
ultivariable analysis has not been reported. Third, the lack
rebrovascular Events at Long-Term Follow-Up
el (p) for each parameter. Abbreviations as in Figure 1.nd Cef systematic performance of diffusion-weighted magnetic
g
c
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567resonance imaging might underestimate the incidence of
clinically silent cerebral infarction after CAS (26). Fourth,
iven its nonrandomized nature, our results cannot be
ompared with clinical trials on CEA and CABG.
onclusions
In patients with COD and concomitant CAD, a combined
percutaneous treatment performed in high-volume centers
skilled for vascular care yields good immediate and long-
term results. Thus, it may be a valuable alternative to the
entirely surgical or hybrid approaches. Further studies are
warranted to confirm the safety and durability of this com-
bined percutaneous approach.
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